Pure Global

Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study - Trial UMIN000049936

Access comprehensive clinical trial information for UMIN000049936 through Pure Global AI's free database. This phase not specified trial is sponsored by Graduate School of Medicine, Osaka University and is currently Recruiting. The study focuses on Non-small cell lung cancer.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
UMIN000049936
Recruiting
Trial Details
University Hospital Medical Information Network โ€ข UMIN000049936
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study

Study Focus

Observational

Sponsor & Location

Graduate School of Medicine, Osaka University

Japan

Timeline & Enrollment

N/A

Mar 02, 2023

N/A

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

University Hospital Medical Information Network

UMIN000049936

Non-Device Trial